CHAD Therapeutics, Inc. engages in the development, manufacture, and marketing of respiratory care devices for the sleep disorder market. The company offers respiratory care devices to enhance the efficiency of oxygen delivery systems for home and hospital treatment of patients who require supplemental oxygen. It develops FloCHANNEL, a diagnostic device that monitors left and right nasal airflow; FloPAP, a treatment device to monitor and control left and right nasal airflow; Simple REM, a diagnostic device that identifies nasal cycle and its correlating effects, and nasal resistance effects, as well as maintains a constant baseline of airflow measurement, and quantifies independent nasal breathing; Rhinomanometer, a nasal function study device, which measures the nasal resistance of patientÂ’s nares individually, enabling a physician to measure and diagnose anatomical disorders, such as deviated septum, nasal polyps, large adenoids, nasal foreign bodies, and hypertrophic turbinate bones; Bifurcated Nasal Oral Cannula, a nasal/oral pneumatic airflow tubing system that is applied to the nose and mouth of a patient; and FloPAP Mask, a patient nasal mask system for the FloPAP device. The company offers its durable medical equipment to ENT specialists, pulmonologists, pediatricians, and primary care physicians. It has license agreements with AirMatrix Technologies and ACOBA, LLC to manufacture, use, and sell devices for the sleep disorder market. The company was founded in 1982 and is based in Chatsworth, California. On January 5, 2009, CHAD Therapeutics, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the Central District of California.

Chad Therapeutics Inc.
10200 Mason Avenue
Suite 114
Chatsworth, CA 91311
United States - Map
Phone: 818-882-0883
Fax: 818-882-1809
Website: http://www.chadtherapeutics.com